Venetoclax

Venetoclax
Clinical data
Pronunciation	/vɛˈnɛtəklæks/; ve-NE-tə-klaks
Trade names	Venclexta, Venclyxto
Other names	GDC-0199, ABT-199, RG-7601
AHFS/Drugs.com	Monograph
MedlinePlus	a616028
License data	US DailyMed: Venetoclax;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	L01XX52 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	>99.9%
Metabolism	Liver (CYP3A4, CYP3A5)
Elimination half-life	~26 hours
Excretion	Feces (>99.9%; 20.8% as unchanged venetoclax)
Identifiers
	IUPAC name 4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
CAS Number	1257044-40-8;
PubChem CID	49846579;
DrugBank	DB11581;
ChemSpider	29315017;
UNII	N54AIC43PW;
KEGG	D10679;
ChEBI	CHEBI:133021;
ChEMBL	ChEMBL3137309;
PDB ligand	LBM (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID30154863 ;
ECHA InfoCard	100.254.611
Chemical and physical data
Formula	C45H50ClN7O7S
Molar mass	868.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CCC(=C(C1)c2ccc(cc2)Cl)CN3CCN(CC3)c4ccc(c(c4)Oc5cc6cc[nH]c6nc5)C(=O)NS(=O)(=O)c7ccc(c(c7)[N+](=O)[O-])NCC8CCOCC8)C;
	InChI InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54) COPY; Key:LQBVNQSMGBZMKD-UHFFFAOYSA-N;

Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).

The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness.

Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.

Clinical data


Pronunciation	/vɛˈnɛtəklæks/ ve-NE-tə-klaks
Trade names	Venclexta, Venclyxto
Other names	GDC-0199, ABT-199, RG-7601
AHFS/Drugs.com	Monograph
MedlinePlus	a616028
License data	US DailyMed: Venetoclax
Pregnancy category	AU: C
Routes of administration	By mouth
ATC code	L01XX52 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	>99.9%
Metabolism	Liver (CYP3A4, CYP3A5)
Elimination half-life	~26 hours
Excretion	Feces (>99.9%; 20.8% as unchanged venetoclax)
Identifiers
IUPAC name 4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
CAS Number	1257044-40-8
PubChem CID	49846579
DrugBank	DB11581
ChemSpider	29315017
UNII	N54AIC43PW
KEGG	D10679
ChEBI	CHEBI:133021
ChEMBL	ChEMBL3137309
PDB ligand	LBM (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID30154863
ECHA InfoCard	100.254.611
Chemical and physical data
Formula	C₄₅H₅₀ClN₇O₇S
Molar mass	868.45 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1(CCC(=C(C1)c2ccc(cc2)Cl)CN3CCN(CC3)c4ccc(c(c4)Oc5cc6cc[nH]c6nc5)C(=O)NS(=O)(=O)c7ccc(c(c7)[N+](=O)[O-])NCC8CCOCC8)C
InChI InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54) COPY Key:LQBVNQSMGBZMKD-UHFFFAOYSA-N